clinical trial · NCT06490939
Clinical Trial of Efepoetin Alfa in Healthy Subjects
Genexine, Inc.·phase1·completed·n = 40
HealthyEfepoetin Alfa
brief summary
An open-label, parallel-group, single-center, Phase I study to compare the pharmacokinetic/pharmacodynamic characteristics, safety, and tolerability of a single intravenous administration of Efepoetin Alfa in healthy subjects
started
Oct 29, 2024
primary completion
Mar 25, 2025
completion
Mar 25, 2025
last updated
Aug 21, 2025
detailed description
This study is to objectively evaluate pharmacokinetics as well as pharmacodynamic responses after a single intravenous administration of the Efepoetin alfa, GX-E4, in healthy Caucasian and Asian volunteers.
official title
An Open-label, Parallel-group, Single-center, Phase I Study to Compare the Pharmacokinetic/Pharmacodynamic Characteristics, Safety, and Tolerability of a Single Intravenous Administration of Efepoetin Alfa in Healthy Caucasian and Asian Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol